The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis
Abstract
in the TriNetX database. The GLP-1RAs include exenatide, liraglutide, dulaglutide, albiglutide, lixisenatide, and semaglutide. Obesity-related comorbid conditions include asthma, metabolic syndrome, gastroesophageal re fl ux disease, metabolic dysfunction – associated steatotic liver disease/steatohepatitis, obstructive sleep apnea, and osteoarthritis. New users were de fi ned as persons who received the fi rst GLP-1RA prescription during the study year/period. The age and sex standardization was conducted using the direct method, with the 2020 U.S. Census as the stand-ardpopulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023) · Clinical Diabetes · doi:10.2337/cd23-0023 · Cited by 132
Monitoring Report: GLP-1 RA Prescribing Trends - September 2024 DataPreprint
Gratzl, S., Rodriguez, P. J., Cartwright, B. M. G., Baker, C., & Stucky, N. L. (2024) · medRxiv · doi:10.1101/2024.01.18.24301500 · Cited by 24
Gregg, L. P., Worsley, M. L., Ramsey, D. J., Segar, M. W., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000266 · Cited by 8
Cited by
Mahase, E. (2024) · BMJ · doi:10.1136/bmj.q1645 · Cited by 72
Macrophages and T cells in metabolic disorder-associated cancers
Taranto, D., Kloosterman, D. J., & Akkari, L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00743-1 · Cited by 82
“…drugs, particularly GLP-1R agonists, whose prescription rates have increased substantially for non-diabetic patients in the USA in recent years 247 , further investigations are warranted to dissect how these therapies alter the immune system and both local and systemic metabolic processes.”
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“In an analysis of one US health systems database a 700% increase in GLP-1 prescribing over the past four years was noted, primarily driven by prescriptions for obesity [138].”
Sheng‐Kai, K., Lo, J., Kyttaris, V. C., Tsokos, G. C., & Costenbader, K. H. (2024) · Arthritis & Rheumatology · doi:10.1002/art.43037 · Cited by 37
“8,9 In contrast, DPP4i, another class of oral hypoglycemic agents, work by preventing the degradation of glucagon-like peptide 1 (GLP1), which stimulates glucose-dependent insulin secretion and suppresses glucagon production, 10 resulting in a modest reduction in hemoglobin A1C (HbA1c).”
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Metadata
- Authors
- Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., Watson, R., Mohamed, G., Lee, G. Y., Huang, P.-C., & Watson, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- Corresponding author
- Yeo, Yee Hui
- Rezaie, Ali
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2024-09
- Volume
- 177
- Issue
- 9
- Pages
- 1289-1291
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4400874445
- Cited by
- 90
- References
- 3
- Citations by year
- 2026: 41 · 2025: 38 · 2024: 11
- FWCI
- 29.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- GLP-1 receptor agonists, prescribing trends, medication use, type 2 diabetes, anti-obesity drugs, prescribing patterns
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Practice Patterns, Physicians', Drug Prescriptions, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis. https://app.cochat.ai/papers/10.7326/m24-0019
- The paper
- Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., Watson, R., Mohamed, G., Lee, G. Y., Huang, P.-C., & Watson, R. (2024). Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis. Annals of Internal Medicine. https://doi.org/10.7326/m24-0019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.